ANTI-lgSF4 ANTIBODY AND UTILIZATION OF THE SAME

Abstract

It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.

1 - 24 . (canceled) 
     
     
         25 . An isolated antibody having specific binding property against IgSF4, which comprises:
 a heavy chain variable region having CDR containing the amino acid sequences of SEQ ID NO.: 50-52 and;   a light chain variable region having CDR containing the amino acid sequences of SEQ ID NO.: 54-56.   
     
     
         26 . The isolated antibody according to  claim 25 , which is a human antibody or a humanized antibody. 
     
     
         27 . The isolated antibody according to  claim 25 , which is IgG, Fab, Fab′, F(ab′)2, scFv, or dsFv antibody. 
     
     
         28 . A therapeutic agent for cancer comprising an antibody as claimed in  claim 25  as an active ingredient. 
     
     
         29 . A reagent comprising an antibody as claimed in  claim 25 , which is used for examination of liver cancer, examination of adult T cell leukemia, study of liver cancer, or study of adult T cell leukemia. 
     
     
         30 . The isolated antibody according to  claim 25 , which comprises:
 a heavy chain variable region and a light chain variable region in a combination of a heavy chain variable region having CDR consisting of CDR1 of SEQ ID NO.:50, CDR2 of SEQ ID NO.:51, and CDR3 of SEQ ID NO.:52, and a light chain variable region having CDR consisting of CDR1 of SEQ ID NO.:54, CDR2 of SEQ ID NO.:55, and CDR3 of SEQ ID NO.:56.